Nasdaq:GRTX

The Company remains committed to its goal of bringing avasopasem to patients and intends to meet with FDA as soon as possible to discuss potential next steps Galera will take actions to…

As previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up Additional data demonstrated improved preservation of…

<!-- Name:DistributionId Value:8785458 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and neck cancer receiving radiotherapy…